I agree, but don't forget the Hervaxx interim data has validated the B Cell platform, and we know it is safe, chances are this will be also and Leslie has been saying they are designing their trials to obtain early readouts or indicators. Something like that, I can't remember her exact words.
IMO only I believe the chances of early efficacy signals is in our favour, and who knows the IDMC may suggest another reign in on numbers required well before Dec 2022.
Time will tell. I will be here in Dec 2022 and well beyond. This company is rapidly being de-risked and their executive team is phenomenal. We and the patients are in great hands.
All the best to the new recruits in this trial. Hope to hear they are around in Dec 2022 also.
Ann: Imugene First Patient Dosed in PD1-VAXX Clinical Trial, page-24
-
- There are more pages in this discussion • 101 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |